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Abstract
The aim of this study was to determine the incidence, clinical features and outcome of invasive fungal disease (IFD) after either
unmanipulated haploidentical haematopoietic stem cell transplantation (HSCT) or human leukocyte antigen (HLA)-matched sibling HSCT.
This was a head-to-head comparative study performed at a single centre. Patients were admitted between 2007 and 2010, and IFD was
evaluated according to the revised EORTC/MSG criteria, with only proven and probable cases included. Of the 1042 consecutive patients
enrolled, 390 received the HLA-matched HSCT and 652 received unmanipulated haploidentical HSCT. A total of 61 (5.8%) patients had IFD,
including 15 proven cases and 46 probable cases. The incidence of IFD after unmanipulated haploidentical HSCT was signiﬁcantly higher than
that after HLA-matched transplantation (7.1% vs. 3.3%, respectively; p 0.007). IFD occurred later in patients receiving HLA-matched
transplantation compared with patients receiving unmanipulated haploidentical HSCT (141.5 vs. 23 days, respectively; p 0.04). In
multivariate analysis, acute graft-versus-host disease (GVHD) grades III to IV (HR = 2.214, 95% CI, 1.139–4.304; p 0.019), extensive chronic
GVHD (HR = 2.413, 95% CI, 1.377–4.228; p 0.002) and haploidentical transplantation (HR = 2.648, 95% CI, 1.111–6.310; p 0.028) were
identiﬁed as signiﬁcant risk factors associated with IFD. The response to antifungal therapy and the IFD-attributable mortality were similar
between the two types of transplantation. In conclusion, patients who received unmanipulated haploidentical HSCT had a higher risk of IFD
than those patients who received HLA-matched HSCT, but the prognosis of IFD was not associated with the HLA type.
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Introduction
The use of a haploidentical haematopoietic stem cell transplant
(HSCT) provides a chance for cure among patients without a
human leukocyte antigen (HLA)-matched sibling or unrelated
donor. Extensive in vitro T-cell depletion (TCD) was adopted in
centres in Italy and other countries to prevent graft-ver-
sus-host disease (GVHD) and to overcome the barriers to
engraftment [1,2]. However, due to the poor post-transplant
immune reconstitution caused by the in vitro TCD, invasive
fungal disease (IFD) was an important cause of morbidity and
infection-related mortality [3,4]. A study of 205 patients from
Perugia [5] suggested that the risk of invasive aspergillosis (IA)
after haploidentical transplantation with TCD was 2.7 times
higher than that after HLA-matched transplantation.
To overcome these limitations, researchers from other
transplant centres have focused on unmanipulated allografts
with post-transplant immune suppression. In recent years,
researchers at Peking University developed a novel approach
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of HLA-mismatched and haploidentical blood and marrow
transplantation without in vitro TCD [6,7]. With this protocol,
relapse rates, transplant-related mortality (TRM), leuke-
mia-free survival (LFS) and overall survival (OS) were compa-
rable to those of HLA-matched sibling transplantation [8].
While the immune reconstitution after unmanipulated haplo-
identical transplantation improved [9], it is still unknown
whether the incidence of IFD is decreased to a level
comparable to that of HLA-matched transplantation. In our
previous report, 291 patients who received unmanipulated
haploidentical transplantation were reviewed according to the
EORTC 2002 criteria [10]. The 1-year cumulative incidence of
fungal infection was 13.1%. However, a direct comparison with
HLA-matched sibling transplantation has not been conducted.
In the present study, we compare the incidence of IFD
among patients who received HLA-matched vs. haploidentical
HSCT between 2007 and 2010 at the Peking University
Institute of Hematology.
Patients and Methods
Patient cohort and follow-up
Patients who received allogeneic stem cell transplantation from
either HLA-matched sibling donors (MSD) or related haplo-
identical donors (HID) between January 2007 and December
2010 were consecutively enrolled. All patients signed informed
consent forms prior to treatment, and the treatment pro-
gramme was approved by the Ethics Committee of the Peking
University People’s Hospital. Patients who received a second
transplantation were excluded. The last follow-up was on 31
December 2011. Of the total patient population, 291 who
received a HID transplantation between January 2007 and
December 2008 were previously reported [10].
Transplantation procedure
The method of transplantation has been described in previous
reports [6,8]. The conditioning regimen consisted of a
modiﬁed busulfan (BU) and cyclophosphamide (CY) regimen
in most MSD transplantations; however, for HID transplanta-
tions, most patients received a regimen of the BU and CY plus
antithymocyte globulin (ATG, Thymoglobulin; Genzyme,
Cambridge, MA, USA) 2.5 mg/kg/day for 4 days. Cyclosporine
(CSP) plus short-term methotrexate(MTX)and mycophenolate
mofetil (MMF) were administered for the prevention of
graft-versus-host disease. On day +1, MTX (15 mg/m2) was
administered intravenously and then 10 mg/m2 were given on
days +3, +6 and +11 after transplantation. Four doses of MTX
were given to HID transplantation patients while only the ﬁrst
three doses were given to MSD transplantation patients.
Intravenous cyclosporine (2.5 mg/kg twice a day) was started
on day 9 and continued until patients were able to tolerate
oral medication. Thereafter, CSP was given orally twice daily
with target trough levels of 150–250 ng/mL. MMF (7.5 mg/kg
twice daily) was begun on day 9 and discontinued on day 14
in the HLA-matched patients. However, in mismatched
patients, discontinuation of MMF was on days 30–60, based
on the presence or absence of GVHD.
Outcomes assessed
The primary endpoint for the study was the occurrence of IFD,
and the secondary endpoints were response to antifungal
therapy and IFD-attributable mortality. Patients suspected of
IFD were evaluated with high-resolution computed tomogra-
phy, cultures of clinical specimens, and tests for detection of
galactomannan and beta-1,3-D-glucan. A diagnosis of proven
or probable IFD was determined by the revised European
Organization for Research and Treatment of Cancer and
Mycoses Study Group (EORTC/MSG) criteria [11]; only
proven and probable cases were included in the determination
of the cumulative incidence of IFD.
The day of diagnosis was the day on which the ﬁrst
diagnostic microbiological test was performed. The timing of
IFD following HSCT was classiﬁed as early ( 40 days) or late
(>40 days), and the infection was classiﬁed as non-dissemi-
nated or disseminated based on evidence of an infection in at
least two non-contiguous sites.
The response to therapy at 12 weeks after diagnosis was
based on a previously published report [12]. Complete
response (CR) means resolution of all attributable symptoms
and signs of disease and radiological abnormalities, and
mycological evidence of eradication of disease. Partial response
(PR) means improvement in attributable symptoms and signs
of disease and radiological abnormalities, and evidence of
clearance of cultures or reduction of fungal burden. A CR and
PR were regarded as successful treatment, while a stable
response, disease progression and death were regarded as a
poor response. Invasive fungal disease was regarded as the
attributable cause of death when the patient died of progres-
sive organ failure in the absence of other co-morbidities
believed to have caused death.
Underlying disease was classiﬁed as high-risk or stan-
dard-risk. High-risk disease included acute leukaemia either in
non-remission or in the third or greater complete remission,
and chronic myeloid leukaemia in the blast phase; standard-risk
disease included all other diagnoses.
Statistical analysis
In calculating the cumulative incidence of IFD, death before the
occurrence of IFD was treated as a competing risk. Multivariate
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analyses were performed to determine risk factors associated
with the occurrence of IFD, including the following: gender, age,
underlying disease (standard-risk vs. high-risk), the haemato-
poietic cell transplantation-speciﬁc co-morbidity index
(HCT-CI), number of previous chemotherapy regimens, donor
type (HLA-matched sibling vs. haploidentical donors), prior IFD
history (with or without), prophylaxis for IFD (ﬂuconazole vs.
other drugs), acute GVHD (grade 0–II vs. grade III–IV), and
chronic GVHD (non or limited vs. extensive). The HCT-CI was
determined according to the Seattle scale [13]. Variables with
p-values <0.20 in univariate models were entered into Cox
regression models, and two-sided tests were considered to be
signiﬁcant at p-values of 0.05.
Logistic regression was performed to determine factors
associated with response rate to antifungal therapy and
attributable mortality in patients with IFD. Variables tested in
the analysis included gender, underlying disease (standard-risk
vs. high-risk), donor type (MSD vs. HID), prior IFD history,
time of IFD (early vs. late), proven vs. probable, disseminated
vs. non-disseminated, concurrent acute GVHD, concurrent
chronic GVHD, neutropenia (deﬁned as 2 days with count of
<500 neutrophils/lL), monocytopenia (deﬁned as 2 days with
count of <100 monocytes/lL) and lymphopenia (deﬁned as
2 days with a count of <300 lymphocytes/lL). The mortality
attributable to IFD was estimated with cumulative incidence
curves in which deaths due to causes other than IFD were
considered to be competing risk events.
Results
A total of 1042 patients were enrolled, including 390 patients
who received MSD transplantation and 652 patients who
received HID transplantation. The median follow-up for
survivors was 1030 days (range 367–1817). The characteristics
of all HSCT recipients are summarized in Table 1. Most
patients (71.7%) were diagnosed with acute leukaemia, and
almost all (94.8%) received a combination graft from granu-
locyte colony-stimulating factor (G-CSF)-primed bone marrow
and peripheral blood stem cells. About 176 (16.9%) patients
had a prior history of IFD. About 802 (77.0%) patients received
antifungal prophylaxis with oral ﬂuconazole (200 mg/day), 14
(1.3%) patients received voriconazole, 17 (1.6%) received
amphotericin B, 126 (12.1%) received itraconazole injections, 5
(0.5%) received caspofungin, 37 (3.6%) received micafungin and
41 (3.9%) patients received itraconazole oral solution.
Comparison of IFD by type of transplantation
A total of 61 (5.8%) patients were diagnosed with IFD,
including 14 (23.0%) proven cases and 47 (77.0%) probable
cases. The 1-year cumulative incidence of IFD in the HID
group was signiﬁcantly higher than that in the MSD group
(7.1% vs. 3.3%; p 0.007) (Fig. 1). The incidence of IFD in the
HID group and the MSD group at day 40 was 4.3% and 1.0%,
respectively, and at day 100 was 5.2% and 1.3%, respectively.
IFD occured earlier in patients who underwent HID trans-
plantation (23 days vs. 141.5 days; p 0.04).
The ratio of proven to probable cases was not different
between the two transplantation types (MSD, 1/13; HID, 13/
47; p 0.156). Aspergillus was the major pathogen identiﬁed in
IFD in both MSD transplantation and HID transplantation, and
the proportion of Aspergillus infections showed no difference
between the two transplantation types (80% (4/5) vs. 65.2%
TABLE 1. Patient characteristics
Haploidentical
(n = 652)
Matched-sibling
(n = 390) p Value
Age, years (median, range) 25 (3–57) 38 (5–59) <0.001
Gender, male (%) 404 (61.9) 247 (63.3) 0.692
Underlying disease (%)
AML 280 (42.9) 161 (41.3)
ALL 233 (35.7) 73 (18.7)
CML 75 (11.5) 93 (23.8)
MDS 40 (6.2) 35 (9.0)
AA 11 (1.7) 15 (3.8)
MM 2 (0.3) 1 (0.3)
NHL 10 (1.5) 10 (2.6)
Other 1 (0.2) 2 (0.5)
High-risk disease (%) 98 (15.0) 54 (13.8) 0.17
Previous chemotherapy
regimen (median, range)
4 (0–8) 4 (0–29) 0.92
HCT-CI (%)
0–1 537 (82.4) 312 (80) 0.20
 2 115 (17.6) 78 (20)
Mismatched HLA locus (%)
3 374 (57.4) 0 (0) <0.001
2 214 (32.8) 0 (0)
1 59 (9.0%) 0 (0%)
0 5 (0.8%) 390 (100%)
Conditioning regimen (%)
BU/CY 0 (0) 312 (80.0)
BU/CY + ATG 649 (99.5) 0 (0)
CY/ATG 0 (0) 10 (2.6)
BU/FLU 0 (0) 65 (16.7)
TBI-based 1 (0.2) 3 (0.7)
Other 2 (0.3) 0 (0)
Graft source (%)
BM + PB 642 (98.5) 346 (88.7)
BM 1 (0.2) 0 (0)
PB 9 (1.3) 44 (11.3)
Prior IFD history (%) 106 (16.3) 70 (17.9) 0.267
Fluconazole for IFD
prevention (%)
504 (77.3) 298 (76.4) 0.290
Time of neutrophil
engraftment, days
(median, range)
13 (8–31) 16 (9–25) <0.01
Time of platelet
engraftment,
days (median, range)
16 (7–195) 13 (7–120) <0.01
Time to onset of aGVHD,
days (median, range)
28 (7–100) 39 (15–105) 0.14
aGVHD grade III–IV (%) 79/643 (12.3) 19/388 (4.6) <0.01
Time to onset of cGVHD,
days (median, range)
150 (86–581) 150 (80–760) 0.85
Extensive cGVHD (%) 136/601 (22.7) 119/373 (32.0) 0.14
AML, acute myeloid leukaemia; ALL, acute lymphoblastic leukaemia; CML, chronic
myelogenous leukaemia; MDS, myelodysplastic syndrome; AA, aplastic anaemia;
MM, multiple myeloma; NHL, non-Hodgkin’s lymphoma; HCT-CI, haematopoietic
cell transplantation-speciﬁc co-morbidity index; HLA, human leukocyte antigen;
BU, busulfan; CY, cyclophosphamide; FLU, ﬂudarabine; ATG, antithymocyte
globulin; TBI, total body irradiation; BM, bone marrow; PB, peripheral blood; IFD,
invasive fungal disease; aGVHD, acute graft-versus-host disease; cGVHD, chronic
graft-versus-host disease.
Data shown are numbers of patients and percentages, unless otherwise stated.
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(15/23); p 0.886). However, it is noteworthy that the two
Mucormycosis infections that occurred were after haploidenti-
cal transplantation (Table 2).
Although not statistically signiﬁcant, there was a trend for
more disseminated infections in patients receiving HID trans-
plantation compared with MSD transplantation (14/47 (29.8%)
vs. 2/14 (14.3%), respectively; p 0.318). Nine (19.1%) of the 47
cases of IFD in the HID group involved the central nervous
system (CNS), but none of the 14 IFD cases in the MSD group
had an infection in the CNS.
Risk factors for invasive fungal disease
Univariate analysis revealed that high-risk underlying disease,
HID transplantation, delayed neutrophil recovery, delayed
platelet recovery, acute GVHD grades III to IV and extensive
chronic GVHD were associated with an increased risk of IFD
(Table 3). Acute GVHD grades III to IV (HR = 2.214; 95% CI,
1.139–4.304; p 0.019), extensive chronic GVHD (HR = 2.413;
95% CI, 1.377–4.228; p 0.002) and HID transplantation
(HR = 2.648; 95% CI, 1.111–6.310; p 0.028) remained signif-
icant in the multivariable model (Table 3).
When early IFD and late IFD were analysed separately, HID
transplantation (HR = 4.219; 95% CI, 1.473–12.083; p 0.007)
was identiﬁed as the only risk factor for early IFD in
multivariable analysis, while extensive chronic GVHD
(HR = 3.022; 95% CI, 1.437–6.354; p 0.004) was identiﬁed as
the only risk factor for late IFD in multivariable analysis.
Outcome of invasive fungal disease
The median time from IFD diagnosis to the last follow-up was
231 days (range 0–1,463). At the last follow-up, only 24
(39.3%) patients were still alive. Of the 37 patients who died,
22 of these deaths could be attributed to IFD. The mortality
rate attributed to IFD at 1 year after diagnosis was 30.6%. The
response to antifungal therapy at the 12th week after diagnosis
was 55.7% (34/61 patients), including a CR of 18.0% (11/61
patients) and a PR of 37.7% (23/61 patients).
When the outcomes of IFD for MSD and HID recipients
were compared, no signiﬁcant differences were found for
IFD-attributable mortality and response to antifungal therapy.
The IFD-attributable mortality in MSD and HID patients was
30.0% (4/14 patients) and 30.9% (18/47 patients), respectively
(p 0.905) (Fig. 2). The response to antifungal therapy in MSD
and HID patients was 50.0% (7/14 patients) and 57.4% (27/47
patients), respectively (p 0.761).
However, in the logistic regression analysis, disseminated
infection was associated with a high attributable mortality
(p 0.019) and a poor response to antifungal therapy (p 0.043).
Discussion
This is the ﬁrst study to directly compare IFD incidence and
characteristics after HLA-matched transplantation and haplo-
identical transplantation. The large patient sample and the
highly homogeneous population give reliability to the study’s
ﬁndings. The important ﬁndings include: (i) unmanipulated
haploidentical transplantation has a higher incidence of IFD
compared with HLA-matched sibling transplantation; (ii) IFD
occurred earlier in haploidentical transplantation recipients
but there was no difference in the infection pattern between
the two types; and (iii) the prognosis of IFD was not associated
with the type of transplantation.
Some multicentre studies on different transplantation
donors have been published previously: the TRANSNET data,
the PATH study and the SEIFEM-2004B study [14–16].
However, the populations and transplantation regimens were
highly heterogeneous, and only a minor percentage of the
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FIG. 1. Incidence of IFD after allogeneic stem cell transplantation.
The incidence of IFD after haploidentical transplantation was signiﬁ-
cantly higher than after HLA-matched sibling transplantation (p <0.01).
TABLE 2. Fungi identiﬁed in patients with IFD
Early IFD Late IFD
MSD HID MSD HID
Candida
Candida albicans 0 3 0 0
Candida glabrata 0 2 0 0
Candida krusei 0 1 0 1
Candida tropicalis 0 1 1 0
Aspergillus
Aspergillus fumigatus 0 1 3 1
Aspergillus ﬂavus 0 0 0 1
Aspergillus species 0 4 1 6
Othera 0 0 0 2
MSD, matched sibling transplantation; HID, haploidentical transplantation.
aMucormycosis.
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patients received haploidentical transplantation. Furthermore,
all of these studies used the 2002 EORTC criteria for IFD. In a
retrospective analysis, 81% of the possible cases and 75% of
the probable cases of IFD deﬁned by the EORTC/MSG 2002
criteria were categorized as non-classiﬁable when the 2008
EORTC/MSG deﬁnitions were used [17]. This makes compar-
ing data from studies using the 2002 vs. the 2008 criteria very
difﬁcult. Our previous report reviewed 291 patients who
received an unmanipulated haploidentical transplantation using
the 2002 criteria, and 13.1% of these patients had a fungal
infection. When using the 2008 criteria, the incidence of IFD
after haploidentical transplantation was only 7.1% after 1 year.
The incidence did not decrease; rather, it was the impact of
the different criteria.
Our results suggest that fungal-speciﬁc immune recovery is
delayed with unmanipulated haploidentical HSCT in compar-
ison with HLA-matched transplantation. It is known that CD4+
T cells play an important protective role in the host antifungal
reaction [18], although the population of CD4+ T cells is not
proportional to the fungal-speciﬁc immunity [10]. Our pub-
lished data [19] suggest that the immune reconstitution of
CD4+ T cells after non-TCD haploidentical transplantation is
signiﬁcantly slower than after HLA-matched transplantation in
the ﬁrst 90 days.
A further consideration is that the antithymocyte globulin
(ATG) used in haploidentical transplantation can extensively
deplete CD3+ T cells, and this depletion can last for a long
time. Data from the study by Zhang et al. showed that in the
setting of unmanipulated haploidentical transplantation, the
serum ATG concentration is higher than the minimum
effective concentration until 90 days after dosing [20]. This is
perhaps another factor associated with the higher rate and
earlier occurrence of IFD after haploidentical transplantation.
However, this hypothesis needs more direct evidence.
Haploidentical vs. HLA-matched sibling transplantation was
not signiﬁcantly associated with response to antifungal therapy
and IFD-attributed mortality. Rather, the characteristics of
IFD, such as the infection type (disseminated infection vs.
non-disseminated infection), grade of diagnosis (proven vs.
probable) and time of infection (early vs. late) had an impact on
the IFD prognosis. The PATH study showed that patients with
IFD after HLA-matched transplantation had the same progno-
sis as patients with IFD after transplantation from an alterna-
tive donor [15], but only 5% of the population received
haploidentical transplantation and the study did not compare
the two transplantation types directly. Other studies suggest
that patients infected with IFD after an HSCT from an
alternative donor have a poor prognosis [16,21,22], but none
of these studies performed a prospective comparison.
In conclusion, IFD infections in patients receiving an
unmanipulated haploidentical HSCT occurred more frequently
than in patients receiving HLA-matched HSCT. This reﬂects
TABLE 3. Risk factors associated with IFD after HSCT
Variables
IFD
Univariate analysis (p value)
Multivariate analysis
Yes (n = 61) No (n = 981) p value HR (95% CI)
Age, years (median) 30 30 0.693 – –
Gender (male/female) 43/18 608/373 0.340 – –
High-risk disease (%) 15 (24.6) 137 (13.9) 0.012 0.262 –
Number of previous chemotherapy regimens (median, range) 4 (0–8) 4 (0–29) 0.919 – –
HCT-CI <2, % 88.5% 85.0% 0.20 – –
Prior IFD history (%) 12 (19.7) 164 (16.7) 0.639 – –
HID (%) 47 (77.0) 605 (61.7) <0.001 0.028 2.648 (1.111–6.310)
Prophylaxis with ﬂuconazole (%) 46 (75.4) 756 (77.1) 0.942 – –
Time of neutrophil engraftment, days (median, range) 15 (9–31) 14 (8–31) 0.029 0.094 –
Time of platelet engraftment, days (median, range) 18 (9–188) 14 (7–195) <0.001 0.261 –
Grade III–IV aGVHD (%) 10 (16.4) 88 (8.9) 0.015 0.019 2.214 (1.139–4.304)
Extensive cGVHD (%) 21 (34.4) 179 (18.2) 0.014 0.002 2.413 (1.377–4.228)
IFD, invasive fungal disease; HSCT, haematopoietic stem cell transplantation; HR, hazard ratio; CI, conﬁdence interval; HCT-CI, haematopoietic cell transplantation-speciﬁc
co-morbidity index; HID, haploidentical donors; aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease.
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FIG. 2. The 1-year attributable mortality rates for IFD in patients
receiving HLA-matched sibling transplantation or haploidentical trans-
plantation were similar (30.0% and 30.9%, respectively; p 0.905).
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the difference in immune reconstitution between the two
types of transplantation to some extent. These results
demonstrate that more active prophylactic strategies should
be adopted in the setting of HID transplantation.
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